Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Mr Edoardo Camenzind,
Dr. Roxana Mehran,
By Edoardo Camenzind, FESC (Nancy, France)View Discussant report
Open the PresentationWatch the Webcast
List of Authors: Edoardo Camenzind, Ph Gabriel Steg, Laura Mauri, William Wijns for the PROTECT Steering Committee and Investigators
CHU Nancy, Institut Lorrain du Coeur et des Vaisseaux, F54511 Vandoeuvre-Lès-Nancy, France. (E Camenzind MD); AP-HP, Hôpital Bichat, F75018, Paris, France (Ph G Steg MD); Harvard Medical School and Brigham and Women’s Hospital, Boston, MA (L Mauri MD); Cardiovascular Center, OLV Hospital, Aalst, Belgium (W Wijns MD)
Aims To compare the long-term clinical safety between two drug-eluting stents with different healing characteristics in the Patient Related Outcomes with Endeavor (E-ZES) versus Cypher (C-SES) Stenting Trial (PROTECT). At 3 years, there was no difference in the primary outcome of definite or probable stent thrombosis or in the other main secondary clinical outcomes consisting of the composite of death or myocardial infarction. Pre-specified five year clinical follow-up was analysed.Methods and Results PROTECT was a prospective, open-label randomized controlled superiority trial powered to look at differences in long-term clinical safety, including stent thrombosis. Dual antiplatelet therapy (DAPT) was prescribed for ≥3 months and up to 12 months based on current guidelines. PROTECT enrolled 8791 patients undergoing elective or emergency PCI to E-ZES or C-SES. There was no difference in DAPT usage between the two groups up to 5 years. At 5 year follow-up, the primary outcome occurred in 1.7% of E-ZES vs. 2.8% of C-SES patients (HR 0.60 [95% CI 0.45–0.81], p=0.0007) (Figure 1 and 2). The composite of all-cause death or large myocardial infarction occurred in 8.2% of E-ZES vs 9.6% of C-SES treated patients (HR 0.85 [95% CI 0.73–0.98], p=0.021) and of all-cause death or all myocardial infarction occurred in 10.8% of E-ZES vs 12.7% of C-SES treated patients (HR 0.85 [95% CI 0.75–0.96], p=0.008) (Figure 3).Conclusions Drug-eluting coronary stents with different healing characteristics demonstrated different late safety profiles: after 5 years, compared to C-SES, E-ZES reduced the risk of stent thrombosis and the risk of the composite endpoints of death or myocardial infarction. Appropriately-powered large-scale trials with long term follow-up are critical to determine clinical safety and efficacy of implanted coronary stents. Reference online ahead of print PROTECT 4 year result:Wijns W, Steg PG, Mauri L, Boersma E, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Lipsic E, Alamgir F, Rademaker-Havinga T, Boersma E, Radke P, van Leuwen F, Camenzind E, Committee PS, Investigators. Endeavor zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4 year results of the PROTECT randomized trial. European Heart Journal doi:10.1093/eurheartj/ehu318
By Roxana Mehran, FESC (New York, United States of America)See Presenter abstract
Open the presentationWatch the Webcast
Clinical Trial Update Hot Line: Infarction, interventions and outcome